Figure 5From: Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trialDisease-free survival in patients under adjuvant 5-FU/FA versus 5-FU/FA/irinotecan in relation to VEGF-D expression. A. Disease-free survival rates in the total population, B. Patients under adjuvant 5-FU/FA, C. Patients under adjuvant 5-FU/FA/irinotecan.Back to article page